Objectives: Prior data indicate a very rare risk of serious adverse drug reaction (ADR) to ultrasound enhancement agents (UEAs). We sought to evaluate the frequency of ADR to UEA administration in contemporary practice.
Methods: We retrospectively reviewed 4 US health systems to characterize the frequency and severity of ADR to UEA.